UK Faces Growing Pressure Over Palantir’s £330 Million NHS Data Deal

The UK government is facing increasing pressure over its £330 million contract with US technology company Palantir to operate a data platform for the National Health Service (NHS).

The agreement, which was awarded in 2023, covers the NHS Federated Data Platform (FDP). The system is designed to connect information from different parts of the health service and help hospitals coordinate care, manage appointments and make better use of available resources.

However, concerns about patient privacy, data security, public trust and the UK's dependence on US technology have intensified ahead of a contractual break point expected in February 2027.

Growing Opposition to the Palantir Contract

Doctors, campaign groups and some lawmakers have called on the government to reconsider its relationship with Palantir.

In July, the UK Parliament's Health and Social Care Committee urged the government to use the upcoming break clause and begin looking for alternatives to the company's Federated Data Platform. The committee cited concerns about public trust, data security and questions surrounding the platform's effectiveness.

The latest controversy comes as the government reviews whether the contract should continue.

More Than 44,000 People Object to Data Use

The debate intensified after more than 44,000 people reportedly filed legal objections concerning the handling of their health information through the Palantir-supported NHS platform.

The objections are based on data-protection rights and call for NHS England to address concerns about the use, storage and sharing of personal medical information.

Campaign groups have also organized demonstrations, arguing that public confidence is essential when healthcare organizations collect and use sensitive medical information.

NHS Says Patient Data Remains Under Its Control

The NHS has maintained that Palantir does not own patients' medical data.

According to the UK government, Palantir operates as a data processor under NHS instructions, with contractual, technical and organizational controls governing access to information. The government has also stated that sensitive data is stored in the UK and is not used by Palantir for commercial purposes or AI training.

Government information also acknowledges that a limited number of supplier personnel can access identifiable data when required for essential platform administration and maintenance. Such access is subject to approval and auditing controls.

Questions About the Platform's Benefits

Palantir and NHS officials point to several reported improvements associated with the Federated Data Platform.

Government figures say the system has supported more than 100,000 additional procedures, helped reduce hospital discharge delays and supported cancer-care coordination. However, NHS England has cautioned that the available data does not necessarily establish a direct cause-and-effect relationship between the platform and those improvements.

Palantir has separately said that NHS organizations using its technology have enabled more operations and reduced delays in patient discharge. Critics have questioned whether these improvements can be directly attributed to the company's platform.

Concerns About Dependence on US Technology

The dispute has also expanded beyond patient privacy.

Some UK lawmakers have raised concerns about the country's growing dependence on American technology companies for critical public services. The issue has become particularly relevant because Palantir also holds contracts with other UK public-sector organizations, including the Ministry of Defence.

Critics argue that the UK should consider developing or adopting alternative systems that provide greater domestic control over important public-sector data infrastructure.

Palantir's Expanding Role in the UK

Palantir has become increasingly involved in Britain's public sector, with contracts covering healthcare, defence and other government-related services.

The company has defended its work in the UK, saying its technology is helping public services operate more efficiently. Its UK business has also become an important part of the company's international operations.

At the same time, Palantir's involvement in other areas, including defence and immigration enforcement in the United States, has contributed to controversy surrounding its NHS role.

Government Must Decide Before 2027

The UK government now faces a decision over whether to continue the Palantir arrangement when the contractual break clause becomes available.

The debate involves several competing issues, including patient privacy, public trust, technology performance, data governance, cost and national technological independence.

For now, the NHS continues to use the Federated Data Platform while the government reviews the future of the contract. A final decision could determine whether Palantir remains a major technology provider to the UK's health service or whether officials begin moving toward an alternative platform.

Final Thoughts

The Palantir-NHS dispute highlights the challenges governments face when adopting advanced technology to manage sensitive public information.

While officials and Palantir point to operational benefits from the Federated Data Platform, critics continue to raise questions about privacy, transparency and long-term dependence on a foreign technology provider.

With the contract's break point approaching in 2027, the UK's decision will likely remain an important issue for the country's healthcare and technology sectors.